Kalorama: Gene Editing Technologies Market Reaches $382 Million

News provided by

Oct 17, 2016, 09:03 ET

ROCKVILLE, Md., Oct. 17, 2016 /PRNewswire/ -- According to Kalorama Information, the budding global market for gene editing technologies already had estimated revenues of $382.9 million in 2015. The discovery of the CRISPR-based technology has expanded and accelerated the adoption and use of gene editing tools in various fields. Growth is fueled by the growing awareness among scientists of applications of these technologies in fields including biopharmaceutical, agricultural, and industrial products. The healthcare market research firm's report, Gene Editing Markets (CRISPR-based, Zinc Finger Nuclease [ZFN], TALEN, Other), examines the total market for gene editing technologies, providing revenues and forecasts.

Gene Editing Markets (CRISPR-based, Zinc Finger Nuclease [ZFN], TALEN, Other) can be found at Kalorama Information: http://www.kaloramainformation.com/Gene-Editing-CRISPR-10347331/?productid=10347331.

Gene editing is the process of modifying the DNA of a particular organism, by introducing breaks at specific, targeted locations in the genome. In turn, DNA breaks stimulate the cell's internal repair mechanisms, which in the end inactivate a gene or introduce new genes of interest in the target location of the genome. Kalorama thinks the global market for gene editing technologies is a fast-evolving market in which innovation occurs rapidly and scientific knowledge is translated to commercial applications.

"Gene editing has a large variety of commercial applications, such as for therapeutics, crops, animal breeds, and chemicals," said Bruce Carlson, Publisher of Kalorama Information. "At the present time, CRISPR/Cas9, ZFNs, and TALENs are the most used and commercially developed technologies."

The currently available genome editing technologies encompass several classes of programmable nucleases –enzymes. These include mononucleases, zinc finger nucleases (ZFN), transcription activator-like effector nucleases (TALENs), and clustered CRISPR-associated nuclease Cas9. ZFNs and TALENs are naturally occurring enzymes that can be designed in desired combinations and with customized specificities. However, ZFNs and TALENs are difficult to engineer and re-target, and have limited ability to multiplex – perform multiple sets of reactions in parallel.

The CRISPR/Cas9 system is the newest genome editing tool. CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) are direct repeats found in the DNA of many bacteria and archaea – single-celled microorganisms. The CRISPR/Cas9 system was derived from the adaptive immune system that bacteria and archaea develop against foreign material such as viruses. The CRISPR/Cas9 system is composed of a short RNA molecule that guides a Cas9 enzyme to the targeted genomic location; the guide RNA recognizes the targeted sequence via base pairing, and the Cas9 enzyme cleaves the DNA. The CRISPR/Cas9 system can be easily designed to target any location in the genome with high efficiency, and has multiplexing capabilities.

Given its advantages, the CRISPR/Cas9 technology is the most rapidly developing class among the other classes of genome editing technologies, as it is the least expensive, most efficient, versatile, and user friendly. However, all gene editing technologies have certain limitations, among which their off-target cleaving activity is the most concerning aspect, particularly for the application of these technologies in the development of therapeutics.

More than 20 players participate in this market, from large multinational corporations to small, niche life sciences companies. These companies develop and commercialize various products and services for each of the major gene editing technologies. Key players include MilliporeSigma, ThermoFisher Scientific, and OriGene.

Gene Editing Markets (CRISPR-based, Zinc Finger Nuclease [ZFN], TALEN, Other) explores the total market, providing revenues and forecasts, including global revenues and forecast for the gene editing technologies market by type of product, 2014-2020 (reagents & tools, research services, genetically-edited cell lines, genetically-edited animal models, total market); global revenues and forecast for the gene editing technologies market by geographic region, 2014-2020 (North America, Europe, Asia Pacific, rest of world); global revenues and forecast for the gene editing technologies market by application area, 2014-2020 (drug discovery & development, life sciences research, plants/livestock engineering, other areas, total market); estimated market breakdown by type of product, 2015 (%) (reagents & tools, gene editing services, edited cell lines, edited animal models); estimated market breakdown by geographic region, 2015 (%) (North America, Europe, Asia Pacific, rest of world); and estimated market breakdown by application area, 2015 (%) (drug discovery & development, life sciences research, plants/livestock engineering, others).

The report provides as well revenues and forecasts by technology, including global revenues and forecast for the CRISPR-based market by type of product, 2014-2020 (reagents & tools, research services, edited cell lines, edited animal models, total market); global revenues and forecast for the ZFN market by type of product, 2014-2020 (reagents & tools, research services, edited cell lines, edited animal models, total market); global revenues and forecast for the TALEN market by type of product, 2014-2020 (reagents & tools, research services, edited cell lines, edited animal models, total market); and global revenues and forecast for other gene editing technologies market by type of product, 2014-2020 (reagents & tools, research services, edited cell lines, edited animal models, total market).

Please link any media or news references to our reports or data to http://www.kaloramainformation.com/.

About Kalorama Information

Kalorama Information, a division of MarketResearch.com, supplies the latest in independent medical market research in diagnostics, biotech, pharmaceuticals, medical devices and healthcare; as well as a full range of custom research services. Reports can be purchased through Kalorama's website and are also available on www.marketresearch.com and www.profound.com.

We routinely assist the media with healthcare topics. Follow us on Twitter, LinkedIn and our blog at www.kaloramainformation.com.

Press Contact:
Bruce Carlson
212 807 2262
[email protected]

Logo - http://photos.prnewswire.com/prnh/20150831/262422LOGO

SOURCE Kalorama Information